Immune Therapy Can Protect Against or Treat Later Lymphoma
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Immune Therapy Can Protect Against or Treat Later Lymphoma

HOUSTON -- November 3, 2009 -- Specially developed immune system cells that target the common Epstein-Barr virus (EBV) can protect immune-suppressed bone marrow transplant recipients against lymph system disease and cancers that arise from the viral infection, according to a study published in the journal Blood.

“Therapy with EBV-specific CTLs [cytotoxic lymphocytes] was effective for these patients who were severely immune-compromised, as the cells successfully reached the tumour, multiplied and were able to kill tumor cells” said lead author Helen Heslop, MD, Center for Cell and Gene therapy, Baylor College of Medicine, Houston, Texas.

Patients who undergo the transplants are often immune-suppressed. Because most people have been infected with Epstein-Barr virus, the lack of immune protection makes their lymph system vulnerable to adverse effects of the virus, especially lymphomas that can be traced directly back to the infection.

For the study, 114 patients who had received hematopoietic or blood-related stem cell transplants from an unrelated donor or a family member whose bone marrow was not a perfect match also received infusions of immune components called T-cells that were design to target Epstein-Barr virus-infected cells.

The treatment was preventive in 101 patients, none of whom developed lymphomas associated with Epstein-Barr virus infection. Eleven of 13 patients who had this disease or symptoms of it had sustained remissions.

Because the cells were marked, researchers determined that the special cells remained in the body for as long as 9 years. The cost of the therapy compared favourably with other treatments for the disorder.

Researchers infused the cells soon after the patients received the stem cell transplants, which could account for its success, said Dr. Heslop.

“With such a promising therapy, it’s important that it is not only effective, but that it is a cost-effective option for high-risk patients,” said Heslop.

SOURCE: Baylor College of Medicine

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities